Herb Kotz

602 total citations
23 papers, 494 citations indexed

About

Herb Kotz is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Herb Kotz has authored 23 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Herb Kotz's work include Cancer Treatment and Pharmacology (9 papers), Colorectal Cancer Treatments and Studies (4 papers) and Ovarian cancer diagnosis and treatment (4 papers). Herb Kotz is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Colorectal Cancer Treatments and Studies (4 papers) and Ovarian cancer diagnosis and treatment (4 papers). Herb Kotz collaborates with scholars based in United States, Ukraine and Germany. Herb Kotz's co-authors include Susan E. Bates, Maureen Edgerly, Tito Fojo, Elise C. Kohn, Manish Agrawal, Lori M. Minasian, Christina M. Annunziata, Susan Bakke, Ann Rutt and Frank M. Balis and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Herb Kotz

23 papers receiving 477 citations

Peers

Herb Kotz

ONCOL

PRM

Evangelos Bournakis Greece

A. D. Colevas United States

I. Gibbens United Kingdom

F Penault–Llorca France

Morihiko Kimura Japan

P. Ravdin United States

M. Koukourakis Greece

Rita Ruijter Netherlands

R. Mione Italy

O. Rixe France

Evangelos Bournakis Greece

Herb Kotz

267 ×0.8

ONCOL

272 ×1.8

160 ×1.2

PRM

153 ×1.8

39 ×0.5

Citations per year, relative to Herb Kotz Herb Kotz (= 1×) peers Evangelos Bournakis

Countries citing papers authored by Herb Kotz

Since Specialization

Citations

This map shows the geographic impact of Herb Kotz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Herb Kotz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Herb Kotz more than expected).

Fields of papers citing papers by Herb Kotz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Herb Kotz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Herb Kotz. The network helps show where Herb Kotz may publish in the future.

Co-authorship network of co-authors of Herb Kotz

This figure shows the co-authorship network connecting the top 25 collaborators of Herb Kotz. A scholar is included among the top collaborators of Herb Kotz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Herb Kotz. Herb Kotz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Burotto, Mauricio, Maureen Edgerly, Marianne S. Poruchynsky, et al.. (2015). Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma. The Oncologist. 20(7). 725–726. 8 indexed citations

Squires, Jill, John L. Hays, Herb Kotz, et al.. (2011). A pharmacokinetics/pharmacodynamics study of sequence specificity of the PARP inhibitor olaparib with carboplatin in refractory/recurrent women’s cancers: NCT01237067.. Journal of Clinical Oncology. 29(15_suppl). TPS158–TPS158. 2 indexed citations

Kohn, Elise C., Christina M. Annunziata, Lori M. Minasian, et al.. (2011). A phase II study of intermittent sorafenib with bevacizumab in bevacizumab-naive epithelial ovarian cancer (EOC) patients.. Journal of Clinical Oncology. 29(15_suppl). 5019–5019. 12 indexed citations

Annunziata, Christina M., Lori M. Minasian, J. Zujewski, et al.. (2011). Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca).. Journal of Clinical Oncology. 29(15_suppl). 2520–2520. 19 indexed citations

Lee, Jang‐Ming, Gisele Sarosy, Christina M. Annunziata, et al.. (2010). Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. British Journal of Cancer. 102(3). 495–499. 58 indexed citations

Huang, Hui, Michael E. Menefee, Maureen Edgerly, et al.. (2010). A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 16(5). 1634–1641. 34 indexed citations

Stein, Wilfred D., Hui Huang, Michael E. Menefee, et al.. (2009). Other Paradigms: Growth Rate Constants and Tumor Burden Determined Using Computed Tomography Data Correlate Strongly With the Overall Survival of Patients With Renal Cell Carcinoma. The Cancer Journal. 15(5). 441–447. 31 indexed citations

Menefee, Michael E., Hongyun Huang, Maureen Edgerly, et al.. (2008). Effects of the P-glycoprotein (Pgp) antagonist tariquidar (XR-9576; TQD) on Pgp function as well as the toxicity and efficacy of combined chemotherapy in patients with metastatic adrenocortical cancer (mACC). Journal of Clinical Oncology. 26(15_suppl). 2543–2543. 3 indexed citations

Azad, Nilofer S., Christina M. Annunziata, Tristan Barrett, et al.. (2007). Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: Clinical and translational results. Journal of Clinical Oncology. 25(18_suppl). 3542–3542. 21 indexed citations

10.

Gulley, James L., Philip M. Arlen, William L. Dahut, et al.. (2006). A pilot study of a PANVAC-V and PANVAC-F in patients (pts) with metastatic carcinoma. Journal of Clinical Oncology. 24(18_suppl). 2512–2512. 4 indexed citations

11.

Azad, Nilofer S., Edwin M. Posadas, Virginia E. Kwitkowski, et al.. (2006). Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. Journal of Clinical Oncology. 24(18_suppl). 3004–3004. 36 indexed citations

12.

Zhuang, Sen Hong, Manish Agrawal, Maureen Edgerly, et al.. (2005). A Phase I clinical trial of ixabepilone (BMS‐247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer. 103(9). 1932–1938. 61 indexed citations

13.

Menefee, Max G., Herb Kotz, Manish Agrawal, et al.. (2004). A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer. Journal of Clinical Oncology. 22(14_suppl). 4550–4550. 6 indexed citations

14.

Posadas, Edwin M., Mustafa Hussain, Virginia Espina, et al.. (2004). A phase II clinical trial with proteomic profiling of imatinib mesylate in patients with refractory or relapsed epithelial ovarian cancer (EOC). Journal of Clinical Oncology. 22(14_suppl). 9651–9651. 2 indexed citations

15.

Menefee, Michael E., Herb Kotz, Marianne S. Poruchynsky, et al.. (2004). A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer. Journal of Clinical Oncology. 22(14_suppl). 4550–4550. 26 indexed citations

16.

Agrawal, Manish, Maureen Edgerly, Tito Fojo, & Herb Kotz. (2003). Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog. Gynecologic Oncology. 90(1). 96–99. 9 indexed citations

17.

Abraham, Jame, Manish Agrawal, Susan Bakke, et al.. (2003). Phase I Trial and Pharmacokinetic Study of BMS-247550, an Epothilone B Analog, Administered Intravenously on a Daily Schedule for Five Days. Journal of Clinical Oncology. 21(9). 1866–1873. 113 indexed citations

18.

Kwon-Chung, K. J., Brian L. Wickes, Ira F. Salkin, Herb Kotz, & Jack D. Sobel. (1990). Is Candida stellatoidea disappearing from the vaginal mucosa?. Journal of Clinical Microbiology. 28(3). 600–601. 6 indexed citations

19.

Kotz, Herb, et al.. (1985). Oral contraceptives and infertility. Journal of Nurse-Midwifery. 30(5). 293–293. 1 indexed citations

20.

Rutledge, Felix N., et al.. (1965). MESONEPHRIC ADENOCARCINOMA OF THE ENDOMETRIUM; REPORT OF A CASE AND A REVIEW OF THE LITERATURE.. PubMed. 25. 362–70. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact